Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Evans

Showing results (61-70 of 154) with videos related to

Pageof 16
Sort By:
Age and Ageing|October 6, 2022
The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitusMarc Evans, Angharad R Morgan, Sarah Davies, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 16, 2014
Increased Risk of Severe Hypoglycemic Events with Increasing Frequency of Non-severe Hypoglycemic Events in Patients with Type 1 and Type 2 DiabetesSeamus Sreenan, Marc Andersen, Brian Larsen Thorsted, et al.
Diabetes, Obesity & Metabolism|December 28, 2016
An alternative approach to modelling HbA1c trajectories in patients with type 2 diabetes mellitusPhil McEwan, Hayley Bennett, Lei Qin, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 29, 2023
Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UKMarc Evans, Sasha Berry, Samuel J P Malkin, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|December 9, 2019
Optimising the Benefits of SGLT2 Inhibitors for Type 1 DiabetesMarc Evans, Debbie Hicks, Dipesh Patel, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|January 2, 2020
Correction to: Optimising the Benefits of SGLT2 Inhibitors for Type 1 DiabetesMarc Evans, Debbie Hicks, Dipesh Patel, et al.
Diabetes, Obesity & Metabolism|October 4, 2018
Association between diabetic eye disease and other complications of diabetes: Implications for care. A systematic reviewIan Pearce, Rafael Simó, Monica Lövestam-Adrian, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|January 18, 2015
Estimating Cost-Effectiveness in Type 2 Diabetes: The Impact of Treatment Guidelines and Therapy DurationPhil McEwan, Jason Gordon, Marc Evans, et al.
Pharmacoeconomics - Open|May 24, 2026
Validation of the Obesity Lifecycle Model Built to Assess the Cost Effectiveness of Novel Therapies in the Management of ObesityBen Modley, Ahmed Seddik, Marc Evans, et al.
Advances in Therapy|April 18, 2025
Analysis of Tirzepatide Acquisition Costs and Weight Reduction Outcomes in the United Kingdom: Insights from the SURMOUNT-1 StudyMarc Evans, William Evans, Fiona Godbeer, et al.
Pageof 16

Showing results (61-70 of 154) with videos related to

Sort By:
Pageof 16
Age and Ageing|October 6, 2022
The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitusMarc Evans, Angharad R Morgan, Sarah Davies, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 16, 2014
Increased Risk of Severe Hypoglycemic Events with Increasing Frequency of Non-severe Hypoglycemic Events in Patients with Type 1 and Type 2 DiabetesSeamus Sreenan, Marc Andersen, Brian Larsen Thorsted, et al.
Diabetes, Obesity & Metabolism|December 28, 2016
An alternative approach to modelling HbA1c trajectories in patients with type 2 diabetes mellitusPhil McEwan, Hayley Bennett, Lei Qin, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 29, 2023
Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UKMarc Evans, Sasha Berry, Samuel J P Malkin, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|December 9, 2019
Optimising the Benefits of SGLT2 Inhibitors for Type 1 DiabetesMarc Evans, Debbie Hicks, Dipesh Patel, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|January 2, 2020
Correction to: Optimising the Benefits of SGLT2 Inhibitors for Type 1 DiabetesMarc Evans, Debbie Hicks, Dipesh Patel, et al.
Diabetes, Obesity & Metabolism|October 4, 2018
Association between diabetic eye disease and other complications of diabetes: Implications for care. A systematic reviewIan Pearce, Rafael Simó, Monica Lövestam-Adrian, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|January 18, 2015
Estimating Cost-Effectiveness in Type 2 Diabetes: The Impact of Treatment Guidelines and Therapy DurationPhil McEwan, Jason Gordon, Marc Evans, et al.
Pharmacoeconomics - Open|May 24, 2026
Validation of the Obesity Lifecycle Model Built to Assess the Cost Effectiveness of Novel Therapies in the Management of ObesityBen Modley, Ahmed Seddik, Marc Evans, et al.
Advances in Therapy|April 18, 2025
Analysis of Tirzepatide Acquisition Costs and Weight Reduction Outcomes in the United Kingdom: Insights from the SURMOUNT-1 StudyMarc Evans, William Evans, Fiona Godbeer, et al.
Pageof 16